Curasight A/S (NGM:CURAS)

Market Cap	1.12B +265.1%
Revenue (ttm)	n/a
Net Income	-71.43M
EPS	-1.78
Shares Out	47.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,438
Average Volume	127,427
Open	16.75
Previous Close	16.70
Day's Range	16.10 - 16.80
52-Week Range	1.80 - 17.85
Beta	0.16
RSI	61.66
Earnings Date	Feb 26, 2026

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CURAS

Financial Performance

Financial numbers in DKK